News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The 1 Sentence in EXACT Sciences (EXAS)'s Q3 Report That Cost It 16% in October



11/8/2016 5:59:34 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
What happened

Shares of Exact Sciences (NASDAQ:EXAS), a molecular diagnostics company focused on the development of diagnostic tools to detect and prevent cancer, lost 16% of their value in October, according to data from S&P Global Market Intelligence. The reason for the drop can be traced to the company's third-quarter earnings results, which were released on Oct. 26.

So what

For the quarter, Exact Sciences wound up generating $28.1 million from its Cologuard colorectal cancer diagnostic test.

Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES